Research priorities regarding rotavirus vaccine and intussusception: A meeting summary

Vaccine

Volumn 30, Issue SUPPL. 1, 2012, Pages

  Tate, Jacqueline E ^a   Steele, A Duncan ^b   Bines, Julie E ^c,d,e   Zuber, Patrick L F ^f   Parashar, Umesh D ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b PATH   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Intussusception; Rotavirus vaccine

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE;

AFRICA; ARTICLE; ASIA; HUMAN; INFANT; INTUSSUSCEPTION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL;

BIOMEDICAL RESEARCH; HUMANS; INFANT; INTUSSUSCEPTION; RESEARCH; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 84860005243     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.110     Document Type: Article

References (49)

1. World Health Organization. Rotavirus vaccines: an update. Wkly Epidemiol Rec 2009;84(December (50)):533-40.
2. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001, 344(February (8)):564-572.
3. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999;48(July (27)):577-81.
4. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(January (1)):23-33.
5. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(January (1)):11-22.
6. World Health Organization. Safety of rotavirus vaccines: postmarketing surveillance in the WHO Region of the Americas. Wkly Epidemiol Rec 2011;86(February (8)):66-72.
7. Buttery J.P., Danchin M.H., Lee K.J., Carlin J.B., McIntyre P.B., Elliott E.J., et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011, 29(April (16)):3061-3066.
8. Baggs J., Haber P. Continued surveillance for intussusception following RotaTeq in VAERS and VSD. Advisory Committee on Immunization Practices Meeting 2010.
9. Richardson V., Hernandez-Pichardo J., Quintanar-Solares M., Esparza-Aguilar M., Johnson B., Gomez-Altamirano C.M., et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010, 362(January (4)):299-305.
10. Curns A.T., Steiner C.A., Barrett M., Hunter K., Wilson E., Parashar U.D. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010, 201(June (11)):1617-1624.
11. Buttery J.P., Lambert S.B., Grimwood K., Nissen M.D., Field E.J., Macartney K.K., et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J 2011, 30(January (1 Suppl.)):S25-S29.
12. Yen C., Armero Guardado J.A., Alberto P., Rodriguez Araujo D.S., Mena C., Cuellar E., et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr Infect Dis J 2011, 30(January (1 Suppl.)):S6-S10.
13. Quintanar-Solares M., Yen C., Richardson V., Esparza-Aguilar M., Parashar U.D., Patel M.M. Impact of rotavirus vaccination on diarrhea-related hospitalizations among children <5 years of age in Mexico. Pediatr Infect Dis J 2011, 30(January (1 Suppl.)):S11-S15.
14. Raes M., Strens D., Vergison A., Verghote M., Standaert B. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J 2011, 30(July (7)):e120-e125.
15. Paulke-Korinek M., Kundi M., Rendi-Wagner P., de Martin A., Eder G., Schmidle-Loss B., et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011, 29(March (15)):2791-2796.
16. Meeting of the Global Advisory Committee on Vaccine Safety, December 2010. Wkly Epidemiol Rec 2011;86(January (5)):38-43.
17. Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009. Wkly Epidemiol Rec 2009;84(August (32)):325-32.
18. Patel M.M., Clark A.D., Glass R.I., Greenberg H., Tate J., Santosham M., et al. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception. Vaccine 2009, 27(May (22)):2916-2922.
19. Bines J.E., Patel M., Parashar U. Assessment of postlicensure safety of rotavirus vaccines, with emphasis on intussusception. J Infect Dis 2009, 200(November (Suppl. 1)):S282-S290.
20. Bines J.E., Ivanoff B. Acute intussusception in infants and children: incidence, clinical presentation and management: a global perspective 2002, World Health Organization, Geneva.
21. Tate J.E., Simonsen L., Viboud C., Steiner C., Patel M.M., Curns A.T., et al. Trends in intussusception hospitalizations among US infants, 1993-2004: implications for monitoring the safety of the new rotavirus vaccination program. Pediatrics 2008, 121(May (5)):e1125-e1132.
22. Bines J.E., Liem N.T., Justice F.A., Son T.N., Kirkwood C.D., de Campo M., et al. Risk factors for intussusception in infants in Vietnam and Australia: adenovirus implicated, but not rotavirus. J Pediatr 2006, 149(October (4)):452-460.
23. Selvaraj G., Kirkwood C., Bines J., Buttery J. Molecular epidemiology of adenovirus isolates from patients diagnosed with intussusception in Melbourne, Australia. J Clin Microbiol 2006, 44(September (9)):3371-3373.
24. Chang E.J., Zangwill K.M., Lee H., Ward J.I. Lack of association between rotavirus infection and intussusception: implications for use of attenuated rotavirus vaccines. Pediatr Infect Dis J 2002, 21(February (2)):97-102.
25. Centers for Disease Control and Prevention. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48(March (RR-2)):1-20.
26. Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999;48(November (43)):1007.
27. Peter G., Myers M.G. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics 2002, 110(December (6)):e67.
28. Global Advisory Committee on Vaccine Safety, 1-2 December 2005. Wkly Epidemiol Rec 2006;81(January (2)):15-9.
29. Simonsen L., Morens D., Elixhauser A., Gerber M., Van Raden M., Blackwelder W. Effect of rotavirus vaccination programme on trends in admission of infants to hospital for intussusception. Lancet 2001, 358(October (9289)):1224-1229.
30. Ciarlet M., Estes M.K., Conner M.E. Simian rhesus rotavirus is a unique heterologous (non-lapine) rotavirus strain capable of productive replication and horizontal transmission in rabbits. J Gen Virol 2000, 81(May (Pt 5)):1237-1249.
31. Uhnoo I., Riepenhoff-Talty M., Dharakul T., Chegas P., Fisher J.E., Greenberg H.B., et al. Extramucosal spread and development of hepatitis in immunodeficient and normal mice infected with rhesus rotavirus. J Virol 1990, 64(January (1)):361-368.
32. Moser C.A., Dolfi D.V., Di Vietro M.L., Heaton P.A., Offit P.A., Clark H.F. Hypertrophy, hyperplasia, and infectious virus in gut-associated lymphoid tissue of mice after oral inoculation with simian-human or bovine-human reassortant rotaviruses. J Infect Dis 2001, 183(April (7)):1108-1111.
33. Bernstein D.I., Glass R.I., Rodgers G., Davidson B.L., Sack D.A. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. JAMA 1995, 273(April (15)):1191-1196.
34. Joensuu J., Koskenniemi E., Pang X.L., Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997, 350(October (9086)):1205-1209.
35. Perez-Schael I., Guntinas M.J., Perez M., Pagone V., Rojas A.M., Gonzalez R., et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997, 337(October (17)):1181-1187.
36. Rennels M.B., Glass R.I., Dennehy P.H., Bernstein D.I., Pichichero M.E., Zito E.T., et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996, 97(January (1)):7-13.
37. Santosham M., Moulton L.H., Reid R., Croll J., Weatherholt R., Ward R., et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997, 131(October (4)):632-638.
38. Meeting of the Immunization Strategic Advisory Group of Experts, April 2009-conclusions and recommendations. Wkly Epidemiol Rec 2009;84(June (23)):220-36.
39. Benninghoff B. Impact of Rotarix™ on the burden of severe rotavirus disease and new challenges. 9th international rotavirus symposium 2010.
40. Patel M. Analysis of post-licensure evaluation of intussusception risk with Rotarix in Brazil and Mexico. Advisory Committee on Immunization Practices Meeting 2010.
41. Colindres R. GSK human rotavirus vaccine Rotarix: PASS Mexico study update. Advisory Committee on Immunization Practices Meeting 2010.
42. Mast T.C. Post-Licensure Safety Study for RotaTeq® Review of Intussusception (IS) Data. Advisory Committee on Immunization Practices Meeting 2010.
43. Rotavirus vaccination and risk of intussusception: a report of TGA's investigation of a possible safety signal; 2011 [cited 20 April 2011]. Available from: http://www.tga.gov.au/safety/alerts-medicine-rotavirus-110225.htm.
44. Steele A.D., De Vos B., Tumbo J., Reynders J., Scholtz F., Bos P., et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2008, 28(September (39)):6542-6548.
45. Zaman K., Sack D.A., Yunus M., Arifeen S.E., Podder G., Azim T., et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009, 27(February (9)):1333-1339.
46. Bines J.E., Liem N.T., Justice F., Son T.N., Carlin J.B., de Campo M., et al. Validation of clinical case definition of acute intussusception in infants in Viet Nam and Australia. Bull World Health Organ 2006, 84(7):569-575.
47. Ciarlet M., Conner M.E. Evaluation of rotavirus vaccines in small animal models. Methods Mol Med 2000, 34:147-187.
48. Nylund C.M., Denson L.A., Noel J.M. Bacterial enteritis as a risk factor for childhood intussusception: a retrospective cohort study. J Pediatr 2010, 156(May (5)):761-765.
49. Clark A., Sanderson C. Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 2009, 373(May (9674)):1543-1549.